Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

MAXIPHARMA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   2.1% 1.0% 1.3% 1.0% 1.2% 1.2% 9.7% 9.5%   Credit score (0-100)   69 88 81 86 83 80 25 26   Credit rating   BBB A A A A A BB BB   Credit limit (kDKK)   0.1 228.0 84.7 286.3 139.6 94.9 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,611 1,432 1,534 1,683 2,022 1,825 0.0 0.0   EBITDA   746 575 645 711 978 538 0.0 0.0   EBIT   679 508 580 654 970 538 0.0 0.0   Pre-tax profit (PTP)   -130.4 992.3 956.9 1,267.2 339.8 290.4 0.0 0.0   Net earnings   -101.8 774.0 746.4 988.3 264.9 226.5 0.0 0.0   Pre-tax profit without non-rec. items   -130 992 957 1,267 340 290 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   197 130 64.8 7.7 0.0 0.0 0.0 0.0   Shareholders equity total   2,074 2,848 3,395 3,683 3,744 3,766 2,862 2,862   Interest-bearing liabilities   2,227 1,062 32.7 214 566 602 0.0 0.0   Balance sheet total (assets)   4,965 5,084 4,873 5,069 5,097 5,206 2,862 2,862   Net Debt   213 -460 -1,919 -1,808 -1,087 -1,448 -2,862 -2,862     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,611 1,432 1,534 1,683 2,022 1,825 0.0 0.0   Gross profit growth   15.9% -11.1% 7.2% 9.7% 20.2% -9.8% -100.0% 0.0%   Employees   2 2 2 2 2 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   4,965 5,084 4,873 5,069 5,097 5,206 2,862 2,862   Balance sheet change%   36.0% 2.4% -4.1% 4.0% 0.6% 2.1% -45.0% 0.0%   Added value   746.4 574.7 645.0 711.4 1,027.1 538.1 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -134 -134 -130 -114 -15 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   42.1% 35.4% 37.8% 38.9% 48.0% 29.5% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   16.6% 21.3% 20.4% 25.8% 19.5% 19.7% 0.0% 0.0%   ROI %   19.9% 26.0% 27.5% 34.9% 24.1% 23.3% 0.0% 0.0%   ROE %   -4.6% 31.4% 23.9% 27.9% 7.1% 6.0% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   41.8% 56.0% 69.7% 72.7% 73.5% 72.3% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   28.6% -80.0% -297.6% -254.2% -111.2% -269.0% 0.0% 0.0%   Gearing %   107.4% 37.3% 1.0% 5.8% 15.1% 16.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   61.8% 4.7% 10.8% 13.8% 166.3% 123.8% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.2 1.5 2.5 2.4 2.5 2.6 0.0 0.0   Current Ratio   1.6 2.2 3.2 3.5 3.6 3.5 0.0 0.0   Cash and cash equivalent   2,013.5 1,521.9 1,952.2 2,023.0 1,652.8 2,049.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -310.6 2,269.6 2,933.1 2,363.1 1,936.0 1,570.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   373 287 323 356 514 269 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   373 287 323 356 489 269 0 0   EBIT / employee   340 254 290 327 485 269 0 0   Net earnings / employee   -51 387 373 494 132 113 0 0